D. Velligan, P. Weiden, M. Sajatovic, J. Scott, D. Carpenter et al., Strategies for Addressing Adherence Problems in Patients with Serious and Persistent Mental Illness: Recommendations From the Expert Consensus Guidelines, Journal of Psychiatric Practice, vol.16, issue.5, pp.306-324, 2010.
DOI : 10.1097/01.pra.0000388626.98662.a0

J. Kreyenbuhl, E. Slade, D. Medoff, C. Brown, B. Ehrenreich et al., Time to discontinuation of first- and second-generation antipsychotic medications in the treatment of schizophrenia, Schizophrenia Research, vol.131, issue.1-3, pp.127-132, 2011.
DOI : 10.1016/j.schres.2011.04.028

J. Lacro, L. Dunn, C. Dolder, S. Leckband, and D. Jeste, Prevalence of and Risk Factors for Medication Nonadherence in Patients With Schizophrenia, The Journal of Clinical Psychiatry, vol.63, issue.10, pp.892-909, 2002.
DOI : 10.4088/JCP.v63n1007

D. Velligan, P. Weiden, M. Sajatovic, J. Scott, D. Carpenter et al., The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness, J Clin Psychiatry, vol.70, pp.1-46, 2009.

C. Adams, M. Fenton, S. Quraishi, and A. David, Systematic meta-review of depot antipsychotic drugs for people with schizophrenia, The British Journal of Psychiatry, vol.179, issue.4, pp.290-299, 2001.
DOI : 10.1192/bjp.179.4.290

T. Kishimoto, A. Robenzadeh, C. Leucht, S. Leucht, K. Watanabe et al., Long-Acting Injectable vs Oral Antipsychotics for Relapse Prevention in Schizophrenia: A Meta-Analysis of Randomized Trials, Schizophrenia Bulletin, vol.40, issue.1, 2013.
DOI : 10.1093/schbul/sbs150

C. Leucht, S. Heres, J. Kane, W. Kissling, J. Davis et al., Oral versus depot antipsychotic drugs for schizophrenia???A critical systematic review and meta-analysis of randomised long-term trials, Schizophrenia Research, vol.127, issue.1-3, pp.83-92, 2011.
DOI : 10.1016/j.schres.2010.11.020

. Schizophrenia, Core interventions in the treatment and management of schizophrenia in primary and secondary care (update), 20704054.

R. Buchanan, J. Kreyenbuhl, D. Kelly, J. Noel, D. Boggs et al., The 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary Statements, Schizophrenia Bulletin, vol.36, issue.1, pp.71-93, 2010.
DOI : 10.1093/schbul/sbp116

H. Takeuchi, T. Suzuki, H. Uchida, K. Watanabe, and M. Mimura, Antipsychotic treatment for schizophrenia in the maintenance phase: A systematic review of the guidelines and algorithms, Schizophrenia Research, vol.134, issue.2-3, pp.219-225, 2012.
DOI : 10.1016/j.schres.2011.11.021

T. Barnes, A. Shingleton-smith, and C. Paton, Antipsychotic long-acting injections: prescribing practice in the UK, The British Journal of Psychiatry, vol.195, issue.52, pp.37-42, 2009.
DOI : 10.1192/bjp.195.52.s37

M. Patel and A. David, Why aren't depot antipsychotics prescribed more oftenandwhatcanbedoneaboutit?Adv Psychiatr Treat, pp.203-213, 2011.
DOI : 10.1192/apt.11.3.203

A. Fourrier, I. Gasquet, M. Allicar, M. Bouhassira, J. Lepine et al., Patterns of neuroleptic drug prescription: a national cross-sectional survey of a random sample of French psychiatrists, British Journal of Clinical Pharmacology, vol.56, issue.1, pp.80-86, 2000.
DOI : 10.1046/j.1365-2125.2000.00108.x

S. Heres, J. Hamann, W. Kissling, and S. Leucht, Attitudes of Psychiatrists Toward Antipsychotic Depot Medication, The Journal of Clinical Psychiatry, vol.67, issue.12, pp.1948-1953, 2006.
DOI : 10.4088/JCP.v67n1216

H. Autorité and D. Santé, Guide d'analyse de la littérature et gradation des recommandations

S. Leucht, C. Corves, D. Arbter, R. Engel, C. Li et al., Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis, The Lancet, vol.373, issue.9657, pp.31-41, 2009.
DOI : 10.1016/S0140-6736(08)61764-X

S. Leucht, K. Komossa, C. Rummel-kluge, C. Corves, H. Hunger et al., A Meta-Analysis of Head-to-Head Comparisons of Second-Generation Antipsychotics in the Treatment of Schizophrenia, American Journal of Psychiatry, vol.166, issue.2, pp.152-163, 2009.
DOI : 10.1176/appi.ajp.2008.08030368

H. Autorité and D. Santé, Elaboration de recommandations de bonne pratique. Méthode " Recommandations par consensus formalisé " . 2011: [http://www.has-sante.fr/portail/upload/docs/application

L. Samalin, S. Guillarma, P. Courtet, M. Abbar, S. Lancrenon et al., Methodological differences between pharmacological treatment guidelines for bipolar disorder: what to do for the clinicians?, Comprehensive Psychiatry, vol.54, issue.4, pp.309-320, 2013.
DOI : 10.1016/j.comppsych.2012.10.001

P. Llorca, P. Courtet, P. Martin, M. Abbar, C. Gay et al., Screening and management of bipolar disorders: methodology, Encephale, pp.36-76, 2010.

P. Llorca, P. Courtet, P. Martin, M. Abbar, C. Gay et al., Screening and management of bipolar disorders: results, Encephale, pp.36-86, 2010.

G. Alexopoulos, D. Jeste, H. Chung, D. Carpenter, R. Ross et al., The expert consensus guideline series. Treatment of dementia and its behavioral disturbances. Introduction: methods, commentary, and summary, Postgrad Med, pp.6-22, 2005.

G. Alexopoulos, I. Katz, C. Reynolds, D. Carpenter, and J. Docherty, The expert consensus guideline series. Pharmacotherapy of depressive disorders in older patients, Postgrad Med, pp.1-86, 2001.

M. Allen, G. Currier, D. Carpenter, R. Ross, and J. Docherty, Introduction: Methods, Commentary, and Summary, Journal of Psychiatric Practice, vol.11, issue.Supplement 1, pp.5-108, 2005.
DOI : 10.1097/00131746-200511001-00002

D. Kahn, G. Sachs, D. Printz, D. Carpenter, J. Docherty et al., Medication Treatment of Bipolar Disorder 2000: A Summary of the Expert Consensus Guidelines, Journal of Psychiatric Practice, vol.6, issue.4, pp.197-211, 2000.
DOI : 10.1097/00131746-200007000-00004

J. Kane, S. Leucht, D. Carpenter, and J. Docherty, The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary, J Clin Psychiatry, vol.64, pp.5-19, 2003.

W. Fleischhacker, Second-generation antipsychotic long-acting injections: systematic review, The British Journal of Psychiatry, vol.195, issue.52, pp.29-36, 2009.
DOI : 10.1192/bjp.195.52.s29

L. Samalin, A. Nourry, T. Charpeaud, and P. Llorca, Whatistheevidencefortheuseof second-generation antipsychotic long-acting injectables as maintenance treatment in bipolar disorder?, Nord J Psychiatry, 2013.

M. Lambert, D. Marinis, T. Pfeil, J. Naber, D. Schreiner et al., Establishing remission and good clinical functioning in schizophrenia: Predictors of best outcome with long-term risperidone long-acting injectable treatment, European Psychiatry, vol.25, issue.4, pp.220-229, 2010.
DOI : 10.1016/j.eurpsy.2009.09.001

R. Emsley, P. Oosthuizen, L. Koen, D. Niehaus, R. Medori et al., Oral versus injectable antipsychotic treatment in early psychosis: Post hoc comparison of two studies, Clinical Therapeutics, vol.30, issue.12, pp.2378-2386, 2008.
DOI : 10.1016/j.clinthera.2008.12.020

R. Emsley, P. Oosthuizen, L. Koen, D. Niehaus, R. Medori et al., Remission in patients with first-episode schizophrenia receiving assured antipsychotic medication: a study with risperidone long-acting injection, International Clinical Psychopharmacology, vol.23, issue.6, pp.325-331, 2008.
DOI : 10.1097/YIC.0b013e32830c2042

B. Kim, S. Lee, T. Choi, S. Suh, Y. Kim et al., Effectiveness of risperidone long-acting injection in first-episode schizophrenia: In naturalistic setting, Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol.32, issue.5, pp.1231-1235, 2008.
DOI : 10.1016/j.pnpbp.2008.03.012

J. Olivares, K. Alptekin, J. Azorin, F. Canas, V. Dubois et al., Psychiatrists’ awareness of adherence to antipsychotic medication in patients with schizophrenia: results from a survey conducted across Europe, the Middle East, and Africa, Patient Preference and Adherence, vol.7, pp.121-132, 2013.
DOI : 10.2147/PPA.S37534

L. Samalin, T. Charpeaud, O. Blanc, S. Heres, and P. Llorca, Clinicians??? Attitudes Toward the Use of Long-Acting Injectable Antipsychotics, The Journal of Nervous and Mental Disease, vol.201, issue.7, pp.553-559
DOI : 10.1097/NMD.0b013e31829829c4

. Heress, . Hamannj, . Mendelr, . Wickelmaierf, . Pajonkfg et al., Identifying the profile of optimal candidates for antipsychotic depot therapy, Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol.32, issue.8, pp.1987-1993, 2008.
DOI : 10.1016/j.pnpbp.2008.09.025

P. Weiden, C. Kozma, A. Grogg, and J. Locklear, Partial Compliance and Risk of Rehospitalization Among California Medicaid Patients With Schizophrenia, Psychiatric Services, vol.55, issue.8, pp.886-891, 2004.
DOI : 10.1176/appi.ps.55.8.886

L. Gutierrez-rojas, D. Jurado, J. Martinez-ortega, and M. Gurpegui, Poor adherence to treatment associated with a high recurrence in a bipolar disorder outpatient sample, Journal of Affective Disorders, vol.127, issue.1-3, pp.77-83, 2010.
DOI : 10.1016/j.jad.2010.05.021

M. Hassan and M. Lage, Risk of rehospitalization among bipolar disorder patients who are nonadherent to antipsychotic therapy after hospital discharge, American Journal of Health-System Pharmacy, vol.66, issue.4, pp.358-365, 2009.
DOI : 10.2146/ajhp080374

T. Kishimoto, V. Agarwal, T. Kishi, S. Leucht, J. Kane et al., Relapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics, Molecular Psychiatry, vol.361, issue.1, pp.53-66, 2013.
DOI : 10.1038/mp.2011.143

C. Rummel-kluge, K. Komossa, S. Schwarz, H. Hunger, F. Schmid et al., Second-Generation Antipsychotic Drugs and Extrapyramidal Side Effects: A Systematic Review and Meta-analysis of Head-to-Head Comparisons, Schizophrenia Bulletin, vol.38, issue.1, pp.167-177, 2012.
DOI : 10.1093/schbul/sbq042

C. Rummel-kluge, K. Komossa, S. Schwarz, H. Hunger, F. Schmid et al., Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: A systematic review and meta-analysis, Schizophrenia Research, vol.123, issue.2-3, pp.225-233, 2010.
DOI : 10.1016/j.schres.2010.07.012

L. Grimaldi-bensouda, F. Rouillon, B. Astruc, M. Rossignol, J. Benichou et al., Does long-acting injectable risperidone make a difference to the real-life treatment of schizophrenia? Results of the Cohort for the General study of Schizophrenia (CGS), Schizophrenia Research, vol.134, issue.2-3, pp.187-194, 2012.
DOI : 10.1016/j.schres.2011.10.022

H. Detke, D. Mcdonnell, E. Brunner, F. Zhao, S. Sorsaburu et al., Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, I: analysis of cases, BMC Psychiatry, vol.13, issue.suppl 1, p.43, 2010.
DOI : 10.7748/ns1999.06.13.39.47.c2623

T. Barnes, Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology, Journal of Psychopharmacology, vol.356, issue.51, pp.567-620, 2011.
DOI : 10.1097/00004714-200002000-00016

A. Hasan, P. Falkai, T. Wobrock, J. Lieberman, B. Glenthoj et al., World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 2: Update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects, The World Journal of Biological Psychiatry, vol.28, issue.2, pp.2-44, 2013.
DOI : 10.4088/JCP.09m05284yel

T. Moore, R. Buchanan, P. Buckley, J. Chiles, R. Conley et al., The Texas Medication Algorithm Project Antipsychotic Algorithm for Schizophrenia, The Journal of Clinical Psychiatry, vol.68, issue.11, pp.1751-1762, 2007.
DOI : 10.4088/JCP.v68n1115

G. Goodwin, Evidence-based guidelines for treating bipolar disorder: revised second edition--recommendations from the British Association for Psychopharmacology, Journal of Psychopharmacology, vol.23, issue.4, pp.346-388, 2009.
DOI : 10.1177/0269881109102919

G. Malhi, D. Adams, L. Lampe, M. Paton, O. Connor et al., Clinical practice recommendations for bipolar disorder, Acta Psychiatrica Scandinavica, vol.2, issue.s434, pp.27-46, 2009.
DOI : 10.1111/j.1600-0447.2009.01383.x

M. Frye, K. Ha, S. Kanba, T. Kato, S. Mcelroy et al., International Consensus Group on Depression Prevention in Bipolar Disorder, The Journal of Clinical Psychiatry, vol.72, issue.10, pp.1295-1310, 2011.
DOI : 10.4088/JCP.10123co1c

L. Yatham, S. Kennedy, S. Parikh, A. Schaffer, S. Beaulieu et al., Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013, Bipolar Disorders, vol.131, issue.Suppl. 1, pp.1-44, 2013.
DOI : 10.1111/bdi.12025

H. Grunze, E. Vieta, G. Goodwin, C. Bowden, R. Licht et al., The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2012 on the long-term treatment of bipolar disorder, The World Journal of Biological Psychiatry, vol.16, issue.9, pp.154-219, 2013.
DOI : 10.1192/bjp.133.5.429

J. Kane, E. Aguglia, A. Altamura, A. Gutierrez, J. Brunello et al., Guidelines for depot antipsychotic treatment in schizophrenia, European Neuropsychopharmacology Consensus Conference in, pp.55-66, 1998.
DOI : 10.1016/S0924-977X(97)00045-X

J. Kane and C. Garcia-ribera, Clinical guideline recommendations for antipsychotic long-acting injections, The British Journal of Psychiatry, vol.195, issue.52, pp.63-67, 2009.
DOI : 10.1192/bjp.195.52.s63

E. Stip, A. Abdel-baki, D. Bloom, S. Grignon, and M. Roy, Les antipsychotiques injectables ?? action prolong??e: Avis d'experts de l'Association des m??decins psychiatres du Qu??bec, The Canadian Journal of Psychiatry, vol.364, issue.9, pp.367-376, 2011.
DOI : 10.1177/070674371105600608

S. Keith, J. Kane, M. Turner, R. Conley, and H. Nasrallah, Academic highlights: guidelines for the use of long-acting injectable atypical antipsychotics, J Clin Psychiatry, vol.65, pp.120-131, 2004.

J. Hamann, R. Mendel, S. Heres, S. Leucht, and W. Kissling, How much more effective do depot antipsychotics have to be compared to oral antipsychotics before they are prescribed?, European Neuropsychopharmacology, vol.20, issue.4, pp.276-279, 2010.
DOI : 10.1016/j.euroneuro.2010.01.001